Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.19.2
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jan. 14, 2014
Dec. 31, 2015
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2017
Apr. 30, 2013
Commitments and Contingencies [Line Items]            
Research and Development Expense, Total     $ 5,474,000 $ 3,986,000    
Royalty Guarantees, Commitments, Amount     200,000      
Licensing Fees     157,000 $ 104,000    
Long Term Purchase Commitment Expire Date       Dec. 31, 2015    
Operating Leases, Rent Expense     2,100,000      
Commitments [Member]            
Commitments and Contingencies [Line Items]            
Research Services Agreements Value Fulfilling Commitment   $ 3,000,000        
Royalty Guarantees, Commitments, Amount   $ 3,000,000        
License Cost $ 30,627          
Initial license fee 20,000          
Settlement Agreement [Member]            
Commitments and Contingencies [Line Items]            
Prepaid Expense           $ 1,000,000
Amended Agreement [Member]            
Commitments and Contingencies [Line Items]            
Research and Development Expense, Total     2,100,000      
Second Eastern Affiliate [Member]            
Commitments and Contingencies [Line Items]            
Research and Development Expense, Total     1,051,000   $ 852,000  
Natural Resources and Life Sciences, Vienna            
Commitments and Contingencies [Line Items]            
Licensing Fees     33,900      
Minimum [Member] | Commitments [Member]            
Commitments and Contingencies [Line Items]            
License Cost 25,000          
Maximum [Member] | Commitments [Member]            
Commitments and Contingencies [Line Items]            
License Cost $ 150,000          
Fraunhofer [Member]            
Commitments and Contingencies [Line Items]            
Royalty Guarantees, Commitments, Amount     $ 4,000,000      
Other Commitments, Description     the 2013 Settlement Agreement provided that, for a period of up to 15 years, the Company would pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch(TM) or iBioModulator(TM) technology and ten percent (10%) of all receipts derived by the Company from licensing those technologies to third parties.      
iBio CDMO LLC [Member] | Second Eastern Affiliate [Member]            
Commitments and Contingencies [Line Items]            
Operating Leases, Rent Expense     $ 129,000 $ 39,000